Historical coo News Stories
CooperCompanies: Keel Joins Board; June 4 Earnings
CooperCompanies (COO) named Envista CEO Paul Keel to its board effective July 1 and set its Q2 2026 earnings release for June 4. Recent disclosure highlights solid trailing financials, a modest short interest decline, analyst buy consensus, and refreshed guidance after a better-than-expected quarter—concrete items investors will watch ahead of the call.
CooperCompanies Board Adds Paul Keel; Q2 Wed 6/4AM
CooperCompanies announced Paul Keel’s board appointment effective July 1 and set a Q2 earnings webcast for June 4. Recent 13F filings show mixed institutional moves: ProShares trimmed its position while Capital Group’s ETF materially increased exposure — a split that underscores investor differentiation ahead of the webcast.
CooperCompanies (COO): Q2 Call Sets Stock Focus Up
CooperCompanies (COO) announced its Q2 2026 earnings webcast for June 4, 2026. With no other material news in the last week, investors are focused on segment organic growth, margin trends, and capital allocation after a strong Q1 that raised guidance. This article summarizes the latest facts, what to watch on the call, and practical investor takeaways.
CooperCompanies: ESG Push, Guidance Lift Plus Debt
CooperCompanies (COO) moved the needle this week with a high-profile sustainability initiative from CooperVision, continued strong fiscal guidance from Q1, and meaningful financing flexibility after a recent term-loan amendment. These concrete developments — not speculation — shape near-term investor expectations for the vision-care and women’s health leader.
COO: Q1 Beat and Japan MiSight Launch
CooperCompanies reported a solid Q1 FY2026 with revenue growth, stronger EPS, meaningful free cash flow and a $92.5M buyback. Strategic wins — notably the rollout of MiSight® 1 day in Japan and the MADE BETTER™ sustainability initiative — reinforce CooperVision’s premium push and support CooperCompanies’ upgraded FY2026 guidance.
CooperCompanies Q1 Upside, Activists Demand Split!
CooperCompanies reported solid Q1 results and a large share-repurchase while activists press for a split of CooperVision and CooperSurgical. Operational strain at CooperSurgical, including a sharp drop in operating income and IT-control weaknesses, keeps strategic change and governance front-and-center for investors.
COO Q1 Beat: Guidance Raised, Buybacks Accelerate.
CooperCompanies reported a solid Q1 with revenue of $1.024B, stronger margins and an upwardly revised FY26 guidance. With $92.5M in share repurchases and improved operating leverage, the stock reaction hinges on execution in CooperVision and CooperSurgical ahead.
CooperCompanies: Vision Sales Lift COO Share Rally
CooperCompanies (COO) saw a roughly 5% stock uptick after stronger-than-expected contact-lens sales, while a recent term-loan amendment extends debt maturities and expands borrowing flexibility. Together, these developments strengthen near-term cash-flow outlook and strategic optionality for the company.
COO Stock Surges on Q1 Beat, MiSight Uptake Gains!
CooperCompanies (COO) reported a strong fiscal Q1 2026 with a revenue beat, raised guidance, accelerating CooperVision growth driven by MyDay and MiSight, and disciplined cash deployment including buybacks and debt reduction—providing clear, near-term catalysts for the stock.
CooperCompanies: Board Shakeup Spurs COO Rally Now
CooperCompanies (COO) saw a governance change and launched a formal strategic review the past week, accompanied by strong Q4 results, an expanded buyback program and bullish 2026 guidance—moves that pushed shares higher and prompted analyst target upgrades. This article breaks down the concrete developments, financials, and investor implications for the vision-care and women’s-health business units.
COO Upside: March 5 Earnings & Board Shakeup Ahead
CooperCompanies (COO) faces a pivotal week as it reports Q1 on March 5. Board leadership changes, a formal strategic review and activist cooperation have set clear near-term catalysts.
CooperCompanies COO: Board Shakeup Fuels Value Up
CooperCompanies (COO) has moved decisively on governance and capital allocation: a board refresh linked to activist Browning West, fiscal 2025 results showing modest organic growth, a $1B bump to buyback capacity, and a strategic review that could reshape CooperVision and CooperSurgical. These concrete actions — plus FY2026 guidance and cost-savings targets — create a clearer near-term playbook for investors.